Literature DB >> 24845232

Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma.

Kyoichi Kaira1, Yutaka Sunose, Kazuhisa Arakawa, Noriaki Sunaga, Kimihiro Shimizu, Hideyuki Tominaga, Noboru Oriuchi, Shushi Nagamori, Yoshikatsu Kanai, Tetsunari Oyama, Izumi Takeyoshi.   

Abstract

AIMS: ASC amino acid transporter-2 (ASCT2) is highly expressed in cancer cells. However, the clinicopathological significance of ASCT2 expression in pancreatic cancer remains unclear. The aim of this study was to investigate the clinical significance of ASCT2 expression in pancreatic cancer. METHODS AND
RESULTS: Ninety-seven patients with surgically resected pancreatic ductal adenocarcinoma were evaluated. Tumour sections were stained by immunohistochemistry for ASCT2, Ki67, CD34 (to determine microvessel density), phospho-AKT (p-AKT) and phospho-mammalian target of rapamycin (p-mTOR) expression. ASCT2 was expressed in 54% (52/97) of tumours. Statistically significant differences in patient age, T stage, N stage, lymphatic permeation, vascular invasion, Ki67, and CD34 and p-mTOR expression were observed between tumours with and without ASCT2 expression. Multivariate analysis confirmed that vascular invasion, ASCT2 expression and Ki67 expression were independent predictive factors for a poorer prognosis.
CONCLUSIONS: ASCT2 expression plays an important role in tumour cell growth, and is a promising pathological marker for predicting a worse outcome in pancreatic cancer.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  ASCT2; amino acid transporter; pancreatic cancer; prognostic factor

Mesh:

Substances:

Year:  2014        PMID: 24845232     DOI: 10.1111/his.12464

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  20 in total

1.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Authors:  Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

2.  Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer.

Authors:  Kyoichi Kaira; Kazuhisa Arakawa; Kimihiro Shimizu; Noboru Oriuchi; Shushi Nagamori; Yoshikatsu Kanai; Tetsunari Oyama; Izumi Takeyoshi
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

3.  An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.

Authors:  Aya Osanai-Sasakawa; Kenta Hosomi; Yoshiki Sumitomo; Takuya Takizawa; Shiho Tomura-Suruki; Minami Imaizumi; Noriyuki Kasai; Tze Wei Poh; Kazuya Yamano; Wei Peng Yong; Koji Kono; Satoshi Nakamura; Toshihiko Ishii; Ryuichiro Nakai
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

4.  2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.

Authors:  Michael L Schulte; Alexandra B Khodadadi; Madison L Cuthbertson; Jarrod A Smith; H Charles Manning
Journal:  Bioorg Med Chem Lett       Date:  2015-12-11       Impact factor: 2.823

5.  1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell.

Authors:  Xuanzhu Zhou; Wei Zheng; G A Nagana Gowda; Daniel Raftery; Shawn S Donkin; Brian Bequette; Dorothy Teegarden
Journal:  J Steroid Biochem Mol Biol       Date:  2016-05-03       Impact factor: 4.292

Review 6.  The Na+/Cl--Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis.

Authors:  Mohd Omar F Sikder; Shengping Yang; Vadivel Ganapathy; Yangzom D Bhutia
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

7.  Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo.

Authors:  Michael L Schulte; Matthew R Hight; Gregory D Ayers; Qi Liu; Yu Shyr; M Kay Washington; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

Review 8.  Imaging tumor metabolism using positron emission tomography.

Authors:  David Y Lewis; Dmitry Soloviev; Kevin M Brindle
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

9.  Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.

Authors:  Qian Wang; Rae-Anne Hardie; Andrew J Hoy; Michelle van Geldermalsen; Dadi Gao; Ladan Fazli; Martin C Sadowski; Seher Balaban; Mark Schreuder; Rajini Nagarajah; Justin J-L Wong; Cynthia Metierre; Natalia Pinello; Nicholas J Otte; Melanie L Lehman; Martin Gleave; Colleen C Nelson; Charles G Bailey; William Ritchie; John E J Rasko; Jeff Holst
Journal:  J Pathol       Date:  2015-04-07       Impact factor: 7.996

10.  High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma.

Authors:  Yidong Liu; Liu Yang; Huimin An; Yuan Chang; Weijuan Zhang; Yu Zhu; Le Xu; Jiejie Xu
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.